Genetic Technologies Total Assets 2010-2022 | GENE

Genetic Technologies total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Genetic Technologies Annual Total Assets
(Millions of US $)
2022 $15
2021 $17
2020 $10
2019 $2
2018 $5
2017 $9
2016 $10
2015 $17
2014 $6
2013 $9
2012 $17
2011 $9
2010 $7
2009 $14
Genetic Technologies Quarterly Total Assets
(Millions of US $)
2022-06-30 $15
2021-06-30 $17
2020-12-31 $14
2020-06-30 $10
2019-12-31 $3
2019-06-30 $2
2018-12-31 $3
2018-06-30 $5
2017-12-31 $7
2017-06-30 $9
2016-12-31 $12
2016-06-30 $10
2015-12-31 $12
2015-06-30 $17
2014-12-31 $3
2014-06-30 $6
2013-12-31 $14
2013-06-30 $9
2012-12-31 $13
2012-06-30 $17
2011-12-31 $16
2011-06-30 $9
2010-12-31 $12
2010-06-30 $7
2009-12-31 $12
2009-06-30 $14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.005B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $172.495B 10.52
GSK (GSK) United Kingdom $71.890B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.605B 0.00
Arcus Biosciences (RCUS) United States $2.586B 38.81
Biohaven (BHVN) United States $1.141B 0.00
Emergent Biosolutions (EBS) United States $0.599B 4.71
Zymeworks (ZYME) Canada $0.478B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.278B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.046B 0.00
Gelesis Holdings (GLS) United States $0.035B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00